Ascendis Pharma (ASND) reported a Q3 loss late Thursday of 1.72 euros ($1.81) per diluted share, narrower than a loss of 2.88 euros loss a year earlier.
Analysts polled by Capital IQ expected a loss of 1.46 euros.
Revenue for the quarter that ended Sept. 30 was 57.8 million euros, up from 48 million euros a year earlier.
Analysts surveyed by Capital IQ expected 70.3 million euros.
Shares of the company were about 8% lower in recent after-hours activity.
Price: 114.50, Change: -9.78, Percent Change: -7.87
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。